18F-FDG PET Radiomics of Diffuse Large B-cell Lymphoma

Study Overview
=================
Brief Summary
-----------------
This study aims to investigate the prognostic value of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) radiomics in diffuse large B-cell lymphoma (DLBCL) and its additional value to the International Prognostic Index (IPI).

Detailed Description
-----------------
Several studies have shown that 18F-FDG PET radiomics is predictive of survival in DLBCL. However, to the best of the investigator's knowledge, a multi-feature radiomic signature for prognosis assessment of DLBCL has not yet been described. Furthermore, it remains unclear whether PET-based radiomics could add more prognostic values to the IPI in DLBCL. This study aims to develop 18F-FDG PET radiomic signature, and investigate whether the radiomic signature could improve the prognostic value of the IPI score in predicting progression-free survival (PFS) and overall survival (OS) in DLBCL.

Official Title
-----------------
Synergistic Effect of 18F-FDG PET Radiomics and International Prognostic Index on Outcome Prediction in Diffuse Large B-cell Lymphoma

Conditions
-----------------
Lymphoma, Large B-Cell, Diffuse

Intervention / Treatment
-----------------
* Other: FDG PET radiomic feature evaluation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: histopathologically confirmed diffuse large B-cell lymphoma (DLBCL); Over 18 years old when diagnosed; Have undergone pre-treatment 18F-FDG PET/CT; Have been initially treated with the combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) or R-EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin). Exclusion Criteria: Have primary central nervous system (CNS) lymphoma or second primary cancer; Have undergone surgical resection; With an incomplete follow-up.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: FDG PET radiomic feature evaluation|A total of 1245 radiomic features will be calculated and extracted from baseline FDG PET scans. These features include shape features, first order features, textural features and wavelet features. In the second part, based on the results of least absolute shrinkage and selection operator Cox regression algorithm, the most significant radiomic features will be selected to construct the radiomic signature.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall Survival | the period from the initial diagnosis to the death from any cause | From date of the initial diagnosis until the date of death from any cause, whichever came first, up to 8 years | 
| Progression-free Survival | the period from the initial diagnosis to the progression, relapse or death from any cause | From date of the initial diagnosis until the date of first documented progression, relapse or death from any cause, whichever came first, up to 8 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PET; Diffuse large B-cell lymphoma; Prognosis; Radiomics;